UT Health San Antonio’s commitment to our patient’s care and their experience is at the heart of our BetterCare IT initiative that focuses on enhancing our Epic electronic health record (EHR) platform.
For Cancer Research Month, we sat down with Daruka Mahadevan, MD, PhD, Division Chief, Hematology/Oncology, Director of the Institute of Drug Development and the Associate Director for Clinical Research at UT Health San Antonio MD Anderson Cancer Center. He explains his passion for drug discovery and development, and the challenges of bringing new medicines to the clinic.
While people with fair skin are twice as likely to develop skin cancer, there are still risks for people with darker complexion. In fact, when people with darker skin tones develop skin cancer, they often face more advanced and deadly cases than those with a lighter complexion.
The Mays Cancer Center recently conducted a clinical trial combining two drugs in patients with recurrent, high-grade glioblastoma (GBM). Andrew Brenner, MD, PhD, professor of medicine at the UT Health Science Center San Antonio and a specialist in both breast cancer and malignancies of the brain and spinal cord, initiated the clinical trial.